A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL

NCT04841434 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

CNS Lymphoma

Interventions

DRUG: Voraxaze Injectable Product

Sponsor

Charite University, Berlin, Germany